Do we need more anti-hypertensive drugs: lessons from the new biology

An increasing proportion of the adult population receives antihypertensive medication, resulting in a substantial decline in strokes and perhaps myocardial infarction. Shortcomings in current treatments, the importance of heterogeneity and the promise of molecular genetics are discussed.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1995-06, Vol.345 (8964), p.1555-1557
Main Authors: Bianchi, G., Swales, J.D.
Format: Article
Language:English
Subjects:
Angiotensin II - genetics
Animals
Antihypertensive agents
Antihypertensive Agents - therapeutic use
Antihypertensives
Biological and medical sciences
Blood pressure
Cardiovascular disease
Cardiovascular system
Drug therapy
Drugs
Fatty acids
Genetic Markers
Genetics
Glucose
Heart attacks
Heterogeneity
Humans
Hypertension
Hypertension - drug therapy
Hypertension - genetics
Insulin resistance
Ischemia
Medical research
Medical sciences
Meta-Analysis as Topic
Metabolism
Myocardial infarction
Older people
Peptidyl-Dipeptidase A - genetics
Pharmaceutical industry
Pharmacology
Pharmacology. Drug treatments
Polymorphism, Genetic
Potassium
Rats
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An increasing proportion of the adult population receives antihypertensive medication, resulting in a substantial decline in strokes and perhaps myocardial infarction. Shortcomings in current treatments, the importance of heterogeneity and the promise of molecular genetics are discussed.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(95)91094-8